EFFICACY AND POSSIBLE BIOMARKER OF GEMCITABINE AND ERLOTINIB FOR ADVANCED PANCREATIC CANCER

被引：0
|
作者：
Takahashi, Hideaki [1 ]
Kuwahara, Akiko [1 ]
Okuyama, Hiroyuki [1 ]
Ohno, Izumi [1 ]
Shimizu, Satoshi [1 ]
Mitsunaga, Shuichi [1 ]
Shinohara, Akira [2 ]
Kobayashi, Misaki [2 ]
Okusaka, Takuji
Ikeda, Masafumi [1 ]
机构：
[1] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Chiba, Japan
[2] Natl Canc Ctr Hosp East, Div Pharm, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu435.87
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O2-13-4
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Adjuvant Gemcitabine and Erlotinib for Resected Pancreatic Cancer
    Bao, P.
    Ramanathan, R. K.
    Moser, A. J.
    Bahary, N.
    Lembersky, B. C.
    Bartlett, D. L.
    Hughes, S. J.
    Lee, K. K.
    Zeh, H. J.
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 : S66 - S66
  • [22] Flashback Foreword: Erlotinib and Gemcitabine in Pancreatic Cancer
    Ko, Andrew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (30) : 4711 - +
  • [23] Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer
    Eun Kyoung Jeon
    Hye-Sung Won
    Yoon-Ho Ko
    In Seok Lee
    Tae Ho Hong
    Young Kyoung You
    Myung Ah Lee
    Journal of Cancer Research and Clinical Oncology, 2012, 138 : 1625 - 1630
  • [24] Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer
    Jeon, Eun Kyoung
    Won, Hye-Sung
    Ko, Yoon-Ho
    Lee, In Seok
    Hong, Tae Ho
    You, Young Kyoung
    Lee, Myung Ah
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (10) : 1625 - 1630
  • [25] Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis
    Wang, Yuan
    Hu, Guo-fang
    Zhang, Qian-qian
    Tang, Ning
    Guo, Jun
    Liu, Li-yan
    Han, Xiao
    Wang, Xia
    Wang, Zhe-hai
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 1961 - 1972
  • [26] Dose Finding and Early Efficacy Study of Gemcitabine Plus Capecitabine in Combination With Bevacizumab Plus Erlotinib in Advanced Pancreatic Cancer
    Starling, Naureen
    Watkins, David
    Cunningham, David
    Thomas, Janet
    Webb, Janine
    Brown, Gina
    Thomas, Karen
    Oates, Jacqui
    Chau, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5499 - 5505
  • [27] Survival Benefit with the Combination of Docetaxel, Gemcitabine and Erlotinib in Advanced and/or Metastatic Pancreatic Cancer Patients
    Samelis, Georgios F.
    Ekmektzoglou, Konstantinos
    Tsiakou, Andriani
    Giannakaki, Styliani
    Konstadoulakis, Manoussos
    HEPATO-GASTROENTEROLOGY, 2011, 58 (110) : 1776 - 1781
  • [28] Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer: A Systematic Review with Meta-Analysis
    Yang, Zu-Yao
    Yuan, Jin-Qiu
    Di, Meng-Yang
    Zheng, Da-Yong
    Chen, Jin-Zhang
    Ding, Hong
    Wu, Xin-Yin
    Huang, Ya-Fang
    Mao, Chen
    Tang, Jin-Ling
    PLOS ONE, 2013, 8 (03):
  • [29] Combined Efficacy of Nimotuzumab and Gemcitabine on the Treatment of Advanced Pancreatic cancer
    Li, Yi
    Li, Dan
    Liu, Qianqian
    Li, Jun
    PANCREAS, 2024, 53 (06) : e537 - e542
  • [30] JCO Flashback: A Comparison of Erlotinib Plus Gemcitabine vs Gemcitabine Alone in Treating Advanced Pancreatic Cancer (2007)
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (30) : 4713 - 4713
12345